Trials / Completed
CompletedNCT02612857
Trial of IMO-8400 in Adult Patients With Dermatomyositis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Idera Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine how safe and effective IMO-8400 is in adults with dermatomyositis.
Detailed description
This study will evaluate the safety and efficacy of IMO-8400 in adults with active dermatomyositis (DM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMO-8400 Dose Group 1 | IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks. |
| DRUG | IMO-8400 Dose Group 2 | IMO-8400 Dose 2 subcutaneous injections once a week for 24 weeks. |
| DRUG | Placebo | normal saline subcutaneous injections once a week for 24 weeks. |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2018-05-16
- Completion
- 2018-06-01
- First posted
- 2015-11-24
- Last updated
- 2019-10-10
- Results posted
- 2019-10-10
Locations
20 sites across 3 countries: United States, Hungary, United Kingdom
Source: ClinicalTrials.gov record NCT02612857. Inclusion in this directory is not an endorsement.